



BOARD OF DIRECTORS

President

Melissa H. Little
*Murdoch Children's Research
Institute and University of
Melbourne, Australia*

President Elect

Haifan Lin
*Yale University School of Medicine,
USA*

Vice President

Amander T. Clark
*University of California, Los
Angeles, USA*

Treasurer

Kenneth S. Zaret
*University of Pennsylvania School
of Medicine, USA*

Clerk

Fiona Doetsch
*Biozentrum at the University of
Basel, Switzerland*

Immediate Past President

Christine L. Mummery
*Leiden University Medical Center,
Netherlands*

Directors

Roger A. Barker
University of Cambridge, UK

Marianne E. Bronner
*California Institute of Technology,
USA*

Melissa Carpenter
ElevateBio, USA

Valentina Greco
*Yale Stem Cell Center, Yale
Medical School, USA*

Konrad Hochedlinger
*Massachusetts General Hospital
and Harvard University, USA*

Jürgen Knoblich
*Institute of Molecular
Biotechnology, Austria*

Arnold R. Kriegstein
*University of California San
Francisco, USA*

Jane S. Lebkowski
Patch Technologies, USA

Charles E. Murry
*Institute for Stem Cell and
Regenerative Medicine, University
of Washington, USA*

Malin Parmar
Lund University, Sweden

Martin F. Pera
The Jackson Laboratory, USA

Lygia da Veiga Pereira
Universidade de São Paulo, Brazil

Mitunori Saitou
Kyoto University, Japan

Takanori Takebe
*Cincinnati Children's Hospital
Medical Center, USA/Tokyo Medical
and Dental University and
Yokohama City University, Japan*

Deepak Srivastava, Ex Officio
*Gladstone Institutes and UCSF,
USA*

Leonard I. Zon, Ex Officio
Boston Children's Hospital, USA

Keith Alm
Chief Executive Officer

September 17, 2021

The Honorable Chiquita Brooks-LaSure
Administrator
Centers for Medicare & Medicaid Services,
Department of Health and Human Services,
Attention: CMS-1753-P,
P.O. Box 8010,
Baltimore, MD 21244-1850

**Re: CY 2022 Medicare Hospital Outpatient Prospective
Payment System and Ambulatory Surgical Center Payment
System Proposed Rule (CMS-1753-P)**

Dear Administrator Brooks-LaSure,

On behalf of the International Society for Stem Cell Research (ISSCR), I write to share our support for the Proposed OPPS APC-Specific Policy: Stromal Vascular Fraction (SVF) Therapy, which eliminates the reimbursement for adipose-derived SVF for osteoarthritis—an unproven treatment. The ISSCR is the leading professional organization of stem cell researchers and represents more than 4,000 members in the United States and around the world. Our members are scientists, clinicians, ethicists, and educators dedicated to the responsible advancement of stem cell research and its translation to the clinic. We are concerned with the premature commercialization of unproven cellular therapies because it puts patients at risk and wastes public and patient resources that should go toward treatments approved by regulators and proven safe and effective.

The clinical use of adipose-derived SVF for osteoarthritis is speculative and needs to be evaluated in well-controlled clinical trials overseen by the U.S. Food and Drug Administration (FDA) to determine whether it is a safe and effective therapy. So far, the clinical trials that have been performed using SVF have tended to be early-stage trials that were not designed to test efficacy – either uncontrolled or with small numbers of patients. Also, some of the trials showed little or no sign of efficacy. There remain no indications for which SVF has been proven to be safe and effective in well-controlled clinical trials.

Promoting excellence in stem cell science and applications to human health.



**INTERNATIONAL
SOCIETY FOR
STEM CELL
RESEARCH**

BOARD OF DIRECTORS

President

Melissa H. Little
Murdoch Children's Research
Institute and University of
Melbourne, Australia

President Elect

Haifan Lin
Yale University School of Medicine,
USA

Vice President

Amander T. Clark
University of California, Los
Angeles, USA

Treasurer

Kenneth S. Zaret
University of Pennsylvania School
of Medicine, USA

Clerk

Fiona Doetsch
Biozentrum at the University of
Basel, Switzerland

Immediate Past President

Christine L. Mummery
Leiden University Medical Center,
Netherlands

Directors

Roger A. Barker
University of Cambridge, UK

Marianne E. Bronner
California Institute of Technology,
USA

Melissa Carpenter
ElevateBio, USA

Valentina Greco
Yale Stem Cell Center, Yale
Medical School, USA

Konrad Hochedlinger
Massachusetts General Hospital
and Harvard University, USA

Jürgen Knoblich
Institute of Molecular
Biotechnology, Austria

Arnold R. Kriegstein
University of California San
Francisco, USA

Jane S. Lebkowski
Patch Technologies, USA

Charles E. Murry
Institute for Stem Cell and
Regenerative Medicine, University
of Washington, USA

Malin Parmar
Lund University, Sweden

Martin F. Pera
The Jackson Laboratory, USA

Lygia da Veiga Pereira
Universidade de São Paulo, Brazil

Mitunori Saitou
Kyoto University, Japan

Takanori Takebe
Cincinnati Children's Hospital
Medical Center, USA/Tokyo Medical
and Dental University and
Yokohama City University, Japan

Deepak Srivastava, Ex Officio
Gladstone Institutes and UCSF,
USA

Leonard I. Zon, Ex Officio
Boston Children's Hospital, USA

Keith Alm
Chief Executive Officer

We are concerned that the premature reimbursement of SVF for osteoarthritis may get abused by unscrupulous businesses seeking to profit from consumer enthusiasm for stem cell research and regenerative medicine. The FDA has issued multiple [warnings](#) about unproven cellular therapies and regenerative medicines because they offer no proven clinical benefits and may harm patients. These businesses have used the ClinicalTrials.gov database to recruit patients by implying that a listing in a government database of clinical trials suggests rigor and legitimacy and in some cases by suggesting this reflects regulatory approval. These businesses may use CMS coverage for their treatments as a token of legitimacy for recruiting patients and persuading private insurers to offer coverage. At best, the products they market are unlikely to provide any benefit to patients. Moreover, we have learned that businesses that are willing to ignore FDA marketing regulations are often also willing to ignore regulations related to good manufacturing processes. Unproven stem cell therapy products have seriously injured patients, causing [tumor growth](#), [blindness](#), and [bacterial infections](#). Reimbursement for unproven and unapproved therapies must be halted as it places unnecessary economic burdens on health systems and patients.

Thank you for considering our views on the Proposed OPPS APC-Specific Policy: Stromal Vascular Fraction (SVF) Therapy. If the ISSCR can clarify any of these views or be of assistance, please contact Eric Anthony, ISSCR's Director of Policy at eanthony@isscr.org.

Sincerely,

Melissa H. Little
President, ISSCR
Murdoch Children's Research Institute and
University of Melbourne, Australia

Promoting excellence in stem cell science and applications to human health.

5215 Old Orchard Road, Suite 270
Skokie, Illinois, USA 60077

T +1 224 592 5700
F +1 224 365 0004

info@isscr.org
isscr.org